APA

De Groot S., Blommestein H. M., Redekop W. K., Sleijfer S., Kiemeney L. A. L. M., Oosterwijk E. & Uyl-de Groot C. A. (20170914). Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. : PloS one.

Chicago

De Groot S, Blommestein H M, Redekop W K, Sleijfer S, Kiemeney L A L M, Oosterwijk E and Uyl-de Groot C A. 20170914. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. : PloS one.

Harvard

De Groot S., Blommestein H. M., Redekop W. K., Sleijfer S., Kiemeney L. A. L. M., Oosterwijk E. and Uyl-de Groot C. A. (20170914). Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. : PloS one.

MLA

De Groot S, Blommestein H M, Redekop W K, Sleijfer S, Kiemeney L A L M, Oosterwijk E and Uyl-de Groot C A. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. : PloS one. 20170914.